Skip Ribbon Commands
Skip to main content

​Impact of Digital Transformation & AI on Precision Medicine by Mr Glen de Vries (11 Sep 2019)

Published on: 20-Aug-2019

NTU Institute of Science and Technology for Humanity (NISTH) is organising a talk on 'Impact of Digital Transformation and Artificial Intelligence on Precision Medicine' by Mr Glen de Vries on 11 September 2019, 1:00pm – 2:00pm, at the Arc Lecture Theatre, (LHN-LT).

More data was collected in the life sciences industry in 2017 than ever before. With the rise of modern information systems and digital technologies like artificial intelligence, data analytics and data science capabilities have become critical for research and decision making across industries and academia.

Join this talk with Mr Glen de Vries, President and Co-Founder of Medidata Solutions, to find out more about:

  • Mr de Vries' career journey from being a lab scientist to President and Co-Founder of one of the largest public technology companies founded in New York; including advice from lessons he has learnt
  • The role of digital transformation and artificial intelligence in the age of precision medicine, including how the industry can use it to improve and speed up clinical trial processes and decision making for accelerated outcomes for patients
  • What the life sciences and clinical trials industry will look like in the next 10 years plus the skills and talent that the industry will need

To register, please click here.

About Mr Glen de Vries

Mr Glen de Vries is the President and Co-founder of Medidata Solutions, the leading cloud platform for life sciences research. He has been driving Medidata's mission since the company's inception in 1999: Powering smarter treatments and healthier people. His publications have appeared in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, STAT, Urologic Clinics of North America and TechCrunch. He is a also trustee of Carnegie Mellon University, a Columbia HITLAB Fellow, and a member of the Healthcare Businesswomen's Association European Advisory Board.

Mr de Vries received his undergraduate degree in molecular biology and genetics from Carnegie Mellon University, worked as a research scientist at the Columbia Presbyterian Medical Center and studied computer science at New York University's Courant Institute of Mathematics.

Poster - Impact of Digital Transformation and AI on Precision Medicine.jpg




 Please refer to the video below for replies by Mr Glen de Vries to questions raised by students on 11 Septempber 2019.

  1. Do you think there is a risk that data-based medicine might lead to a reductive understanding of health that doesn't tackle social and economic dimensions?
  2. How do you handle population bias? Which is expected to be the same when sampling for a new experiment, but might be different across experiments (another city)?
  3. Why cancer disease has not progress to use precision medicine using AI in clinical setting?
  4. Regarding the use of SCA, how do we then ensure that the trial remain blinded?
  5. For the case 1 of 5 cured due to new drug, this drug is considered useful? That does mean only 20% chance for curing?

Back to listing

Not sure which programme to go for? Use our programme finder
Loading header/footer ...